

Screening of candidate tumor-suppressor genes in 3p21.3 and investigation of the methylation of gene promoters in oral squamous cell carcinoma

KAI WANG¹, TIANYOU LING¹, HANJIANG WU¹ and JIE ZHANG²

Departments of ¹Stomatology, and ²Ophthalmology, Second Xiangya Hospital,
Central South University, Changsha, Hunan 410011, P.R. China

Received August 30, 2012; Accepted November 9, 2012

DOI: 10.3892/or.2012.2213

Abstract. Oral squamous cell carcinoma (OSCC) is the most common type of head and neck malignant tumor. However, its pathological mechanisms have not yet been elucidated. In the present study, we screened for candidate tumor-suppressor genes (TSGs) related to OSCC among 10 candidate genes located in 3p21.3, a region abundant with TSGs based on previous studies, using semi-quantitative reverse transcription PCR (RT-PCR). Three genes, *GNAT1*, *SEMA3B* and *AXUD1*, with low or no expression in OSCC tissues and the cell line TCA8113 were selected, and the promoter methylation status was further analyzed by methylation-specific PCR (MS-PCR). Hypermethylation in the promoter regions of *SEMA3B* was found in OSCC tissues, and a significant difference in the frequency of methylation of *SEMA3B* was observed between OSCC and non-cancerous tissues. Furthermore, TCA8113 cells treated with 5-Aza-Cdc started to re-express *SEMA3B* at a concentration of 5 μ M or higher. Our study confirmed that three candidate TSGs with low expression may be involved in OSCC and that hypermethylation in promoter regions may contribute to the low expression of *SEMA3B*. These findings offer novel insights for clarifying the molecular mechanisms of tumorigenesis of OSCC as well as for aiding in its clinical diagnosis and therapeutic strategy.

Introduction

Head and neck tumors are the common malignant tumors worldwide, while oral squamous cell carcinoma (OSCC) is the

most prevalent type of head and neck tumor accounting for 2-3% of malignant tumors and 80% of oral and maxillofacial malignant tumors (1,2). Although the techniques of surgical treatment, radiotherapy and chemotherapy for OSCC have progressed in the past few decades, the 5-year survival rate of OSCC patients has shown no noticeable improvement (3,4). Thus, it is crucial to explore the pathological mechanisms of OSCC, and new biomarkers must be identified and used in the detection of precancerous lesions, early diagnosis and therapy of OSCC.

Numerous factors, such as genetic alterations, epigenetic changes and environmental influence, are involved in the development of OSCC. Inactivation and deletion of tumor-suppressor genes (TSGs) play important roles in the development of carcinomas (5). Previous studies have suggested that analyzing the LOH (loss of heterozygosity) in tumor tissues can facilitate the identification of relevant TSGs. For example, *RB* (6), *p53* (7), Wilms tumor (*WT*) (8), cyclin-dependent kinase number 2 (*CDKN2*) (9), adenomatous polyposis coli (*APC*) (10), deleted in pancreatic carcinoma locus 4 (*DPC4*) (11), fragile histidine triad (*FHIT*) (12) and putative protein tyrosine phosphatase gene (*PTEN*) (13,14) have all been identified using LOH analysis. As for OSCC, a high frequency of LOH has been observed on chromosomes 3p, 4q, 5q, 7q, 8p, 9p, 11q, 13q, 18q, 20q, 21q and 22q regions using comparative genomic hybridization and LOH analysis (15-18). Thus, these chromosome segments appear to be target regions where TSGs of OSCC may exist.

Roz *et al* (19) found LOH at one or more loci of chromosome 3p by investigating 30 oral dysplastic lesions, presenting clinically as either erythroplakias or leukoplakias with histopathological features of either severe epithelial dysplasia or carcinoma *in situ*. Furthermore, three discontinuous deletion regions including -3p13-21.1, -3p21.3-5 and -3p25, were detected in patients with precancerous lesions and OSCC, which suggest that alterations of these three regions may be early events in the development of OSCC. Yamamoto *et al* (20) found different degrees of LOH at 3p21.3 in OSCC patients from Japan and India. At the same time, LOH at 3p21-22 was present in other common malignant tumors such as renal carcinoma (21), lung cancer (22), squamous cell carcinoma of the head and neck (23), cervical carcinoma (24) and

Correspondence to: Dr Jie Zhang, Department of Ophthalmology, Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, Hunan 410011, P.R. China
E-mail: zhangjie740410@yahoo.com.cn

Dr Hanjiang Wu, Department of Stomatology, Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, Hunan 410011, P.R. China
E-mail: whj58@fc18.com

Key words: oral squamous cell carcinoma, 3p21.3, gene expression, gene promoter, hypermethylation

Table I. Clinicopathological features of the oral squamous cell carcinoma patients.

Tumor subsite	Cases	Gender		Age (years)	Median age (years)	Lymph node status	
		Male	Female			Positive	Negative
Tongue	28	24	4	17-80	42.1	13	15
Gum	3	2	1	40-61	50.3	1	2
Soft plate	1	1	0	73	73.0	0	1
Floor of the mouth	2	2	0	53	53.0	1	0
Jaw bones	2	1	1	48-59	53.5	2	0

breast cancer (25). Several groups have studied the relevant TSGs for nasopharyngeal carcinoma (NPC) and lung cancer at region 3p21.3 and found that *BLU*, *RASSF1A*, *SEMA3B* and *SEMA3F* play vital roles in the development and progression of NPC or lung cancer (26-30). Similar studies performed in OSCCs revealed that the expression levels of the *LTF*, *LIMD1*, *CACNA2D2*, *RASSF1A*, *CDC25A* and *SCOTIN* genes located at 3p21.3 were decreased by 67.6, 53.2, 23.7, 15.1, 5.3 and 0.58%, respectively. LOH and DNA methylation alterations may account for the abnormal expression of *LTF*, *LIMD1*, *CACNA2D2* and *RASSF1A*.

In the present study, based on the above-mentioned research, bioinformatics analysis was carried out to screen candidate TSGs located at 3p21.3, which to date have not been or have been inadequately studied in OSCC. The methylation state in the promoters of TSGs was also analyzed using methylation-specific PCR (MSP) to explore the role of DNA methylation in the downregulation of TSGs in OSCCs.

Materials and methods

Selecting target genes located at 3p21.3. On the basis of a database search (PubMed, Gene Card, OMIM and Gene Map), using '3p21.3' and 'tumor-suppressor genes' as search terms, 10 genes were selected for analysis based on the following inclusion criteria: i) they were previously reported to exhibit low expression or no expression in other tumor types; and ii) the functions of these genes were not previously studied or inadequately studied in OSCCs.

Cell line and tissues. TCA8113, a tongue cancer cell line, was provided by the Cancer Research Institute of Central South University. TCA8113 cells were cultured in RPMI-1640 supplemented with 10% fetal calf serum at 37°C in a humidified atmosphere with 5% CO₂. Thirty-six pairs of normal and tumor tissues from OSCC patients were obtained from the Hunan Cancer Hospital (Changsha, Hunan, China) and the Second Xiangya Hospital of Central South University (Changsha, Hunan, China) with informed patient consent prior to treatment. All fresh tissues were snap-frozen in liquid nitrogen and stored until required. Clinicopathological information of the patients is presented in Table I.

DNA and RNA extraction. gDNA from all specimens as well as from 1x10⁶ cells was extracted using an improved method for extracting high-molecular-weight DNA with phenol/chlo-

roform according to previously reported procedures (31). Total RNA was isolated from a 100 mg sample from each specimen and a total number of 10⁷ cells using TRIzol reagent according to the manufacturer's protocol (Invitrogen, USA).

Reverse transcription-PCR (RT-PCR). Total RNA was treated with DNase I (Roche Diagnostics, USA) and purified in accordance with the manufacturer's instructions. Reverse transcription was performed with 1 µg of treated total RNA using AMV reverse transcriptase (Promega, Madison, WI, USA). An equal amount of cDNA from each sample was amplified using specific primers for each gene (Table II). The conditions for PCR reactions were as follows: 95°C for 5 min, followed by 30-34 cycles of 94°C for 35 sec, 55-58°C for 35 sec, 72°C for 35 sec, and 72°C for 10 min for the extension. The PCR products were electrophoresed on 1% agarose gel and visualized by ethidium bromide staining.

Gray scale scanning and data analysis. The intensity of each electrophoretic band was measured using ImageMaster VDS (Pharmacia Biotech Inc., Piscataway, NJ), and analyzed by VDS software version 3.0 for band quantification with *GAPDH* as an internal control. The expression levels of target genes in the tumors and normal tissues were investigated after they were normalized by transforming them into two groups according to the ratios of the band intensity of the target genes over that of *GAPDH* for the same sample as previously described (32). A ratio >2 indicated that the corresponding gene was upregulated in OSCC and a ratio <1/2 indicated that the corresponding gene was downregulated in OSCC and all other ratio values indicated that the corresponding genes were expressed at a normal level. Each RT-PCR reaction was carried out in triplicate.

Methylation-specific PCR (MSP). MSP was performed to analyze the methylation state in the promoter regions of the target genes both in OSCC tissues and TCA8113 cells. One microgram gDNA from OSCC tissues and TCA8113 cells was treated with bisulfite, similar to previous methods (33,34). Each sample was amplified with two sets of primers, one set for methylated DNA and one set for unmethylated DNA. When gDNA was treated with bisulfite, the unmethylated cytosine was transformed to uracil while methylated cytosine was unaffected. Thus, the methylated and unmethylated promoters were distinguished by MSP. The primers used for the methylated and unmethylated target gene promoter regions are listed in

Table II. Summary of primer sequences, annealing temperatures and product sizes.

	Sequence (5'-3')	Product size (bp)	Annealing temperature (°C)	Cycles	Ref.
Primer for RT-PCR					
<i>GAPDH</i>	F: GAGATCCCTCCAAAATCAAGTG R: GAGTCCTTCCACGATACCAAAG	282	58	28	
<i>AXUD1</i>	F: TGC GTAACAGTCTCCCACTG R: CCTGATTTTCAGCCCTGTCTC	301	58	30	
<i>BAP1</i>	F: TACGCTACAACCGTGCTGTC R: TCAGCCTCCACACACTTCAG	295	58	30	
<i>FUS1</i>	F: GGATCTGGCTCACGAGTTCT R: GAAGGTTATGGGCCAACAGA	296	55	30	
<i>GNAT1</i>	F: CATCTGCAACCACCGCTAC R: CGCACGTCATGTGGGAATA	221	62	32	
<i>LARS2</i>	F: TTA CTGGATGCCTGTGGATT R: CCCGTTGTGTTTGGACTTAC R: GCCTGCGACATACTGTGGTC	295	56	30	
<i>NPRL2</i>	F: CGCATTGCTATCCAGAACCT R: CTT CATAAGCCCGAACTGGA	300	60	30	
<i>RASSF1A</i>	F: ACACGTGGTGCGACCTCT R: GATGAAGCCTGTGTAAGAACCGTCCT	308	58	32	
<i>SEMA3B</i>	F: GTCCTCTTCATTGGCACAGAC R: GTCGCCATTCTTACGTCTT	345	56	30	
<i>SEMA3F</i>	F: AGTGTC CGTACGATCCCAAG R: ATGACAGGGTTCCTCACGTC	466	58	32	
<i>ZNF35</i>	F: GCGCACATAGGCAGTACTCA R: TGTCTGAAGACCCTGCACTG	296	58	30	
Primer for MSP					
<i>GNAT1</i>	MF: GTAAAAGATATATTTATGGTCGGC MR: CCTCCCAAATAACTAAAATTACGAA UF: AAAAGATATATTTATGGTTGGGTGA UR: CCTCCCAAATAACTAAAATTACAAA	198 195	59 59		
<i>SEMA3B</i>	MF: TGGTTAGGCGGGGTATTTTC MR: TCAACAATAAAAACGAAAACG UF: GTGGTTAGGTGGGGTATTTTTT UR: ATCAACAATAAAAACAAAACA	133 135	54 54		(52)

F, forward primer; R, reverse primer; M, methylation; U, unmethylation.

Table II. The PCR products were analyzed by 1% agarose gel electrophoresis and ethidium bromide staining.

Sequencing. DNA sequencing was carried out to identify the methylated and unmethylated sequences. MSP products were electrophoresed on a 1% agarose gel, and the products were recovered by using the QIAquick Gel Extraction kit (Qiagen, USA). The purified DNA was then cloned into the pMD18-T (Takara, Japan) vector and transformed into *Escherichia coli* strain Top 10 according to the manufacturer's instructions.

The recombinant plasmid DNA extracted from the 5 randomly selected positive clones was used for sequencing.

Treatment of TCA8113 cells with 5-aza-2'-deoxycytidine (5-Aza-Cdc). TCA8113 cells were plated in 6-well plates at a density of 1×10^5 cells/well and cultured overnight. On the morning of the next day, the TCA8113 cells were treated with 5-Aza-Cdc, a type of demethylation reagent, at final concentrations (as control) of 0, 1, 5, 10, 50 and 100 μ M, respectively. After changing the medium and treating cells with 5-Aza-Cdc




Figure 1. Expression of genes located at region 3p12.3 in OSCC tissues by RT-PCR. N, normal tissues as control; T, OSCC tissues.




Figure 2. Relative expression of genes located at region 3p12.3 in OSCC tissues.

once per 24 h for 4 consecutive days, TCA8113 cells were collected for RNA and DNA extraction to perform RT-PCR and MSP analysis.

Statistical analysis. Statistical analysis was performed using the Chi-square test and the Student's t-test. In all analyses, SPSS 11.5 statistical software (SPSS, Chicago, IL) was used, and a P-value <0.05 was considered to indicate a statistically significant result.

Results

Differential expression of the selected genes in OSCC and normal tissues. We selected 10 genes using ‘3p21.3’ and ‘tumor-suppressor genes’ as the search terms in several databases (PubMed, Gene Card, OMIM and Gene Map). The selected genes are listed in Table II.

Differential expression of the target genes was assessed using semi-quantitative RT-PCR combined with Gray Scale Scanning analysis in 12 pairs of OSCC tissues and contralateral normal tissues. The results revealed that the expression of *GNAT1*, *SEMA3B* and *AXUD1* was downregulated or deficient in the OSCC tissues with percentages of 58.3 (7/12), 41.7 (5/12) and 41.7% (5/12), respectively (P<0.05). The expression




Figure 3. Expression of *GNAT1*, *SEMA3B* and *AXUD1* in OSCC tissues and the TCA8113 cell line. (A) Expression of *GNAT1*, *SEMA3B* and *AXUD1* in TCA8113 cells. (B) Verification of the expression of *GNAT1*, *SEMA3B* and *AXUD1* in additional OSCC tissue samples. (C) Verification of relative expression of *GNAT1*, *SEMA3B* and *AXUD1* located at region 3p12.3 in additional OSCC tissues.

of *ZNF35* was upregulated in 33.3% (4/12) of OSCC tissues. No significant difference in expression for *NPRL2*, *BAP1*, *FUS1*, *LARS2*, *RASSF1A* and *SEMA3F* was observed between the OSCC and normal tissues (P>0.05) (Figs. 1 and 2). We selected three downregulated genes, *GNAT1*, *SEMA3B* and *AXUD1*, for further study.

Expression of *GNAT1*, *SEMA3B* and *AXUD1* in OSCC tissues and the TCA8113 cell line. RT-PCR was performed to verify the low expression of *GNAT1*, *SEMA3B* and *AXUD1* in 36 OSCC tissues, corresponding adjacent normal tissues and TCA8113 cells. The results confirmed that the expression of *GNAT1*, *SEMA3B* and *AXUD1* was downregulated or undetectable in 44.4 (16/36) 50 (18/36) and 47.2% (17/36) of the OSCC tissues, respectively, compared with the normal expression of these genes in adjacent normal tissues (P<0.05) (Fig. 3B and C). No expression of *GNAT1* and *SEMA3B* was detected and *AXUD1* was expressed at a normal level in the TCA8113 cells (Fig. 4A) as compared with the expression in OSCC tissues. No significant correlation was observed between the downregulated genes and OSCC metastasis and patient gender when compared with the clinical data (Table III).

Hypermethylation of *GNAT1* and *SEMA3B* in OSCC tissues. We analyzed the methylation status of CpG islands in the promoter region of *GNAT1* and *SEMA3B* in several

Table III. Statistical analysis of the correlation between the downregulated genes and tumor metastasis.

Groups	Cases	Genes					
		<i>AXUD1</i>		<i>GNAT1</i>		<i>SEMA3B</i>	
		N (%)	U (%)	N (%)	U (%)	N (%)	U (%)
Metastasis	17	10 (27.8)	7 (19.4)	10 (27.8)	7 (19.4)	10 (27.8)	7 (19.4)
Non-metastasis	19	9 (25.0)	10 (27.8)	9 (25.0)	10 (27.8)	8 (22.2)	11 (30.1)
χ^2		0.472		0.139		1.003	
P-value		0.492		0.709		0.317	

N, normal expression; U, underexpression.




Figure 4. The hypermethylation status of *GNAT1* and *SEMA3B* was detected in OSCC tissues by MSP. 5-Aza-Cdc partially rescued the expression of *SEMA3B* in TCA8113 cells. (A) Analysis of the methylation of *GNAT1* and *SEMA3B* in OSCC tissues by MSP. N, normal control tissues; T, OSCC tissues; M, methylated; U, unmethylated. (B and C) Expression of *SEMA3B* in TCA8113 cells treated with different concentrations of 5-Aza-Cdc. m, methylated; u, unmethylated. (D and E) Confirmation of the outcome of MSP by sequencing.

OSCC tissue samples and adjacent non-cancerous tissues. Hypermethylation of *GNAT1* and *SEMA3B* was found in 75 (12/16) and 77.8% (14/18) of OSCC tissues, respectively. In the non-cancerous tissues, different levels of methylation were also detected with a percentage of 56.25% (9/16) for *GNAT1* and 38.9% (8/18) for *SEMA3B* (Fig. 4A). The results were also confirmed by the sequencing of the MSP products (Fig. 4D and E). Statistical analysis indicated that there was a significant difference in the frequency of methylation of *SEMA3B* between the OSCC and non-cancerous tissues (χ^2 test, $P=0.018 < 0.05$) (Table IV), while no statistical significance was found

in the frequency of methylation of *GNAT1* between the OSCC and non-cancerous tissues (χ^2 test, $P=0.709 > 0.05$), suggesting that methylation of the promoter plays an important role in the downregulation of the *SEMA3B* gene in OSCC tissues.

5-Aza-Cdc partially recovers the expression of SEMA3B in TCA8113 cells. RNA and DNA were extracted from TCA8113 cells treated with different concentrations of 5-Aza-Cdc for 4 days for expression and methylation analysis of *SEMA3B* by RT-PCR and MSP. The results demonstrated that *SEMA3B* began to be expressed in the TCA8113 cells when treated

Table IV. Statistical analysis of the gene promoter methylation status in OSCC tissues.

Groups	Genes					
	n	<i>GNAT1</i>		n	<i>SEMA3B</i>	
		M (%)	U (%)		M (%)	U (%)
Control	16	9 (56.25)	7 (43.75)	18	7 (38.9)	11 (61.1)
Tumor	16	12 (75.0)	4 (25.0)	18	14 (77.8)	4 (22.2)
χ^2		1.247			5.60	
P-value		0.264			0.018	

Tumor, OSCC tissues; Control, non-cancerous tissues; M, methylated product; U, unmethylated product.

with a concentration of 5-Aza-Cdc at 5 μ M (Fig. 4C). More unmethylated products were amplified from the DNA samples of TCA8113 cells when the higher concentration of 5-Aza-Cdc was administered (Fig. 4B). This suggests that methylation of the promoter plays a critical role in the downregulation of this gene in TCA8113 cells.

Discussion

Inactivation of TSGs and overexpression of oncogenes are the main causes for tumorigenesis. LOH and hypermethylation in promoter regions are the common reasons accounting for the inactivation of TSGs. The short arm of human chromosome 3, a region with a high frequency of LOH, is considered to be rich in TSG-containing sites as indicated by previous studies on lung cancer, breast cancer, ovarian cancer and other malignant tumors (35). Screening tumor-related TSG candidates is an available method based on loss of a chromosome region. Numerous candidate TSGs have been identified in high frequency chromosome-deleted regions such as *DLC-1*, a potential TSG at 8p21, a region frequently deleted in various types of cancers (33,36) and *DMRT1*, *DMRT3* and *DOCK8* located at 9p24.3, a deleted region in squamous cell lung carcinoma (37). In this study, we selected 10 genes including *AXUD1*, *BAP1*, *FUS1*, *GNAT1*, *LARS2*, *NPRL2*, *RASSF1A*, *SEMA3F*, *SEMA3B* and *ZNF35* which were located on region 3p21.3 and analyzed the expression of these genes using RT-PCR to find candidate TSGs in OSCC. Three downregulated genes, *SEMA3B*, *AXUD1* and *GNAT1*, were identified and both *SEMA3B* and *GNAT1* were downregulated in TCA8113 cells.

AXUD1, also termed cysteine-serine-rich nuclear protein 1 gene (*CSRNP1*), was cloned by Ishiguro *et al* (38) while studying the functions of AXIN1 which encodes one of the apoptotic proteins induced by TGF- β in hepatoma carcinoma cells. The full length *AXUD1* cDNA is 3188 bp and encodes a 64-kDa protein containing 596 amino acids and is located mainly in the nucleus. *AXUD1*, a downstream responsive protein for AXIN1, negatively regulates the Wnt pathway which plays an important role in early embryonic development. Studies have shown that the abnormal regulation of the Wnt pathway is related to tumorigenesis. The expression of *AXUD1*, which is

high in normal tissues such as lung, placenta, skeletal muscle, pancreas and leukocytes, was found to be downregulated in lung cancer hepatoma and colorectal carcinoma, suggesting that *AXUD1* may be a candidate TSG (38). Simultaneously, knockdown of the expression of *DAXUD1*, a orthologue of the *AXUD1/CSRNP* family in *Drosophila*, was found to induce imaginal cells to proliferate. Conversely, overexpression of *DAXUD1* retarded cell cycle progression at mitosis behaving similar to a TSG (39). Our study showed that the expression of *AXUD1* was downregulated in 47.2% (17/36) of the OSCC tissues. However, this downregulation had no correlation with patient gender and tumor metastasis, indicating that *AXUD1* may be involved in the early malignant transformation of the oral mucous membrane. The function of this gene in OSCC warrants further study.

Guanine nucleotide-binding protein G (G protein) subunit α -1a encoded by *GNAT1* is an intracellular protein involved in light signal transduction in the retina (40). G protein, as an energy regulator, participates in the regulation of different transmembrane signal transduction pathways (40). Yi *et al* (41) found that expression of *GNAT1* was downregulated in 72.7% (24/33) of nasopharyngeal carcinoma tissues, which was markedly lower than that in chronic nasopharyngitis tissues (100%, 15/15). The study also demonstrated that downregulation of *GNAT1* was associated with LOH, but not with abnormal methylation of the promoter region. In our study, in comparison with the expression in normal control tissues, the expression of *GNAT1* was significantly downregulated in 44.4% of the OSCC tissues ($P=0.037 < 0.05$) and in TCA8113 cells. However, the downregulation of *GNAT1* had no correlation with patient gender and tumor metastasis, suggesting that *GNAT1* may be involved in the early development of OSCC.

SEMA3B, a member of the human semaphoring family is involved in apoptosis (42,43) and in antitumor pathways regulated by p53 (44). *SEMA3B* was cloned by Sekido *et al* (45). *SEMA3B* cDNA encodes an 83-kDa protein of 749 amino acids. Using Northern blot analysis, Lerman and Minna (46) detected wide expression of a 3.4-kb *SEMA3B* transcript that was strongest in placenta, weaker in other tissues including lung and testis and not detectable in small-cell lung cancer cell lines. Missense mutations were found in non-small cell lung cancer cell lines. The authors also showed that *SEMA3B* is likely to be an extracellular secreted protein. Lerman and Minna concluded that *SEMA3B* is an attractive candidate tumor-suppressor gene for methylation and functional analysis. In the present study, we detected the expression of *SEMA3B* mRNA in OSCC tissues and adjacent control tissues. The results showed that the expression level of *SEMA3B* was significantly lower in OSCC tissues than that in control tissues, which was confirmed by undetectable expression of *SEMA3B* in TCA8113 cells. The χ^2 test confirmed that no significant correlation existed between the downregulated expression of *SEMA3B* and patient gender and tumor metastasis.

DNA hypermethylation, one of the most common epigenetic alterations, is involved in inactivation of the expression of many TSGs (47-49). MSP is a technique that has facilitated the detection of promoter hypermethylation at CpG islands in cell lines and clinical samples, including fresh and frozen tissues (50). Riquelme *et al* (51) found that the methylation ratio of the promoter region of *SEMA3B* is 92% (46/50) in

gallbladder carcinoma, suggesting that the methylation of *SEMA3B* may participate in the carcinogenesis and progression of gallbladder carcinoma. The hypermethylation status of *SEMA3B* was also recorded in non-small cell lung cancer decreasing the expression of *SEMA3B* (52,53) and in nasopharyngeal carcinoma for *GNAT1*, however, it did not account for the low expression of *GNAT1* (41).

Thus, MSP was performed with DNA samples from OSCC tissues, control tissues and 5-Aza-Cdc-treated TCA8113 cells. Hypermethylation status of *SEMA3B* in promoter regions was assessed in OSCC tissues, and the expression of *SEMA3B* was partly recovered in TCA8113 cells treated with 5-Aza-Cdc, demonstrating that the hypermethylation status in the promoter region led to, at least partially, low expression of *SEMA3B* in OSCC in accordance with studies in other cancer types (51-53). As for *GNAT1*, although hypermethylation in the promoter regions was observed in OSCC tissues, there was no significant difference in expression between OSCC tissues and control samples. Further studies should be conducted to explore the reasons for the low expression of *GNAT1*.

In conclusion, our study demonstrated that *AXUD1*, *GNAT1* and *SEMA3B*, three candidate TSGs located at 3p21.3, may be involved in the development of OSCC, and methylation in the promoter region plays a critical role in the low expression of *SEMA3B*. These findings may lead to new avenues for the early diagnosis and therapy of OSCC.

References

- Massano J, Regateiro FS, Januario G and Ferreira A: Oral squamous cell carcinoma: review of prognostic and predictive factors. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 102: 67-76, 2006.
- Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. *CA Cancer J Clin* 55: 74-108, 2005.
- Lippman SM and Hong WK: Molecular markers of the risk of oral cancer. *N Engl J Med* 344: 1323-1326, 2001.
- Vokes EE, Weichselbaum RR, Lippman SM and Hong WK: Head and neck cancer. *N Engl J Med* 328: 184-194, 1993.
- Zhou W, Feng X, Li H, *et al*: Inactivation of LARS2, located at the commonly deleted region 3p21.3, by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. *Acta Biochim Biophys Sin* 41: 54-62, 2009.
- Friend SH, Bernards R, Rogelj S, *et al*: A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature* 323: 643-646, 1986.
- Chiba I, Shindoh M, Yasuda M, *et al*: Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. *Oncogene* 12: 1663-1668, 1996.
- Call KM, Glaser T, Ito CY, *et al*: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. *Cell* 60: 509-520, 1990.
- Kamb A, Shattuck-Eidens D, Eeles R, *et al*: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. *Nat Genet* 8: 23-26, 1994.
- Aoki K and Taketo MM: Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. *J Cell Sci* 120: 3327-3335, 2007.
- Hahn SA, Schutte M, Hoque AT, *et al*: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 271: 350-353, 1996.
- Ohta M, Inoue H, Cotticelli MG, *et al*: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. *Cell* 84: 587-597, 1996.
- Li J, Yen C, Liaw D, *et al*: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 275: 1943-1947, 1997.
- Steck PA, Pershouse MA, Jasser SA, *et al*: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nat Genet* 15: 356-362, 1997.
- Imai FL, Uzawa K, Miyakawa A, Shiiba M and Tanzawa H: A detailed deletion map of chromosome 20 in human oral squamous cell carcinoma. *Int J Mol Med* 7: 43-47, 2001.
- Miyakawa A, Wang XL, Nakanishi H, *et al*: Allelic loss on chromosome 22 in oral cancer: Possibility of the existence of a tumor suppressor gene on 22q13. *Int J Oncol* 13: 705-709, 1998.
- Sparano A, Quesnelle KM, Kumar MS, *et al*: Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. *Laryngoscope* 116: 735-741, 2006.
- Yamamoto N, Mizoe J, Numasawa H, Tsujii H, Shibahara T and Noma H: Allelic loss on chromosomes 2q, 3p and 21q: possibly a poor prognostic factor in oral squamous cell carcinoma. *Oral Oncol* 39: 796-805, 2003.
- Roz L, Wu CL, Porter S, *et al*: Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. *Cancer Res* 56: 1228-1231, 1996.
- Yamamoto N, Kuroiwa T, Katakura A, Shibahara T and Choudhury C: Loss of heterozygosity (LOH) on chromosomes 2q, 3p and 21q in Indian oral squamous cell carcinoma. *Bull Tokyo Dent Coll* 48: 109-117, 2007.
- van den Berg A, Dijkhuizen T, Draaijers TG, *et al*: Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development. *Genes Chromosomes Cancer* 19: 228-232, 1997.
- Hung J, Kishimoto Y, Sugio K, *et al*: Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. *JAMA* 273: 1908, 1995.
- Zhu Y, Spitz MR, Zheng YL, Hong WK and Wu X: BPDE-induced lymphocytic 3p21.3 aberrations may predict head and neck carcinoma risk. *Cancer* 95: 563-568, 2002.
- Senchenko V, Liu J, Braga E, *et al*: Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas. *Oncogene* 22: 2984-2992, 2003.
- Senchenko VN, Liu J, Loginov W, *et al*: Discovery of frequent homozygous deletions in chromosome 3p21.3 LUCA and AP20 regions in renal, lung and breast carcinomas. *Oncogene* 23: 5719-5728, 2004.
- Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. *Hum Mol Genet* 10: 687-692, 2001.
- Bird A: DNA methylation patterns and epigenetic memory. *Genes Dev* 16: 6-21, 2002.
- Bird AP: CpG-rich islands and the function of DNA methylation. *Nature* 321: 209-213, 1986.
- Merlo A, Herman JG, Mao L, *et al*: 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. *Nat Med* 1: 686-692, 1995.
- Steinmann K, Sandner A, Schagdarsurengin U and Dammann RH: Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. *Oncol Rep* 22: 1519-1526, 2009.
- Zhang H, Feng X, Liu W, *et al*: Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. *J Cell Biochem* 112: 1832-1843, 2011.
- Zhou W, Feng X, Li H, *et al*: Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12. *Oncol Res* 16: 405-413, 2007.
- Peng D, Ren CP, Yi HM, *et al*: Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. *Acta Biochim Biophys Sin* 38: 349-355, 2006.
- Zhou L, Feng X, Shan W, *et al*: Epigenetic and genetic alterations of the EDNRB gene in nasopharyngeal carcinoma. *Oncology* 72: 357-363, 2007.
- Tuhkanen H, Anttila M, Kosma VM, *et al*: Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. *Int J Cancer* 109: 247-252, 2004.
- Liao YC and Lo SH: Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. *Int J Biochem Cell Biol* 40: 843-847, 2008.

37. Kang JU, Koo SH, Kwon KC and Park JW: Frequent silence of chromosome 9p, homozygous DOCK8, DMRT1 and DMRT3 deletion at 9p24.3 in squamous cell carcinoma of the lung. *Int J Oncol* 37: 327-335, 2010.
38. Ishiguro H, Tsunoda T, Tanaka T, Fujii Y, Nakamura Y and Furukawa Y: Identification of AXUD1, a novel human gene induced by AXIN1 and its reduced expression in human carcinomas of the lung, liver, colon and kidney. *Oncogene* 20: 5062-5066, 2001.
39. Glavic A, Molnar C, Cotoras D and de Celis JF: *Drosophila* Axud1 is involved in the control of proliferation and displays pro-apoptotic activity. *Mech Dev* 126: 184-197, 2009.
40. Ngo JT, Bateman JB, Klisak I, Mohandas T, Van Dop C and Sparkes RS: Regional mapping of a human rod alpha-transducin (GNAT1) gene to chromosome 3p22. *Genomics* 18: 724-725, 1993.
41. Yi HM, Ren CP, Peng D, Zhou L, Li H and Yao KT: Expression, loss of heterozygosity, and methylation of GNAT1 gene in nasopharyngeal carcinoma. *Ai Zheng* 26: 9-14, 2007 (In Chinese).
42. Tomizawa Y, Sekido Y, Kondo M, *et al*: Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. *Proc Natl Acad Sci USA* 98: 13954-13959, 2001.
43. Tse C, Xiang RH, Bracht T and Naylor SL: Human semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. *Cancer Res* 62: 542-546, 2002.
44. Ochi K, Mori T, Toyama Y, Nakamura Y and Arakawa H: Identification of semaphorin3B as a direct target of p53. *Neoplasia* 4: 82-87, 2002.
45. Sekido Y, Bader S, Latif F, *et al*: Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. *Proc Natl Acad Sci USA* 93: 4120-4125, 1996.
46. Lerman MI and Minna JD: The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. *Cancer Res* 60: 6116-6133, 2000.
47. Li W, Li X, Wang W, *et al*: NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma. *Carcinogenesis* 32: 1305-1314, 2011.
48. Mao WM, Li P, Zheng QQ, *et al*: Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer. *Arch Med Res* 42: 182-188, 2011.
49. Liu WB, Ao L, Zhou ZY, *et al*: CpG island hypermethylation of multiple tumor suppressor genes associated with loss of their protein expression during rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine. *Biochem Biophys Res Commun* 402: 507-514, 2010.
50. An JH, Choi A, Shin KJ, Yang WI and Lee HY: DNA methylation-specific multiplex assays for body fluid identification. *Int J Legal Med* 402: 507-514, 2012.
51. Riquelme E, Tang M, Baez S, *et al*: Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. *Cancer Lett* 250: 100-106, 2007.
52. Kuroki T, Trapasso F, Yendamuri S, *et al*: Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. *Cancer Res* 63: 3352-3355, 2003.
53. Ito M, Ito G, Kondo M, *et al*: Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. *Cancer Lett* 225: 131-139, 2005.